SESN - イレブン・バイオセラピュ―ティクス (Sesen Bio Inc.)

SESNのニュース

   Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference  2020/08/05 20:15:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020. The Company will provide an update on the regulatory process in the US and Europe, and the BD process outside the US. Event: Canaccord Genuity 40th Annual
   Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China  2020/07/31 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company in China specializing in the manufacturing and marketing of active pharmaceutical ingredients and drug products, today announced that the companies have entered into an exclusive licensing agreement for the manufacture, development and c
   Sesen Bio to Host Conference Call to Provide OUS Business Update  2020/07/30 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31, 2020 at 8:00 a.m. EDT to provide an Outside the US (“OUS”) and general business update. To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to confe
   Sesen Bio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020. Event: Jefferies Virtual Healthcare Conference Date: June 2, 2020 Time: 8:30 - 8:55 AM ET A live webcast of the Company’s presentation will be accessible from the Investors & Media
   Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability  2020/05/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2020. The Company also provided an update on the progress of manufacturing activities related to demonstrating analytical comparability between clinical batches of Vicinium and validation batches of Vicinium intended for potential future commerci
   Sesen Bio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020. Event: Jefferies Virtual Healthcare Conference Date: June 2, 2020 Time: 8:30 - 8:55 AM ET A live webcast of the Company’s presentation will be accessible from the Investors & Media
   Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability  2020/05/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2020. The Company also provided an update on the progress of manufacturing activities related to demonstrating analytical comparability between clinical batches of Vicinium and validation batches of Vicinium intended for potential future commerci
   Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium®  2020/05/07 20:41:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the regulatory pathway for Vicinium in Europe. The Company’s lead program, Vicinium, also known as VB4-845, is currently in the foll
   Sesen Bio to Host Conference Call to Review First Quarter Financial Results and to Provide Operational Update Highlighting Positive Progress Towards Demonstrating Analytical Comparability  2020/05/04 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11, 2020 at 8:00 a.m. ET to review operating results for the first quarter ended March 31, 2020. The Company will also provide an update on the progress of manufacturing activities related to demonstrating analytical compa
   Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results  2020/03/16 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year ended December 31, 2019. The Company also provided an update highlighting regulatory progress and the commercial opportunity of Vicinium for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC). “2019 was a year of t
   Sesen Bio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020. Event: Jefferies Virtual Healthcare Conference Date: June 2, 2020 Time: 8:30 - 8:55 AM ET A live webcast of the Company’s presentation will be accessible from the Investors & Media
   Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability  2020/05/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2020. The Company also provided an update on the progress of manufacturing activities related to demonstrating analytical comparability between clinical batches of Vicinium and validation batches of Vicinium intended for potential future commerci
   Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium®  2020/05/07 20:41:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the regulatory pathway for Vicinium in Europe. The Company’s lead program, Vicinium, also known as VB4-845, is currently in the foll
   Sesen Bio to Host Conference Call to Review First Quarter Financial Results and to Provide Operational Update Highlighting Positive Progress Towards Demonstrating Analytical Comparability  2020/05/04 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11, 2020 at 8:00 a.m. ET to review operating results for the first quarter ended March 31, 2020. The Company will also provide an update on the progress of manufacturing activities related to demonstrating analytical compa
   Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results  2020/03/16 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year ended December 31, 2019. The Company also provided an update highlighting regulatory progress and the commercial opportunity of Vicinium for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC). “2019 was a year of t

calendar